Short answer
Protagonist Therapeutics, Inc (PTGX) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $56M (up 99.0% year over year) with net income of $4M.
Q1 2026 key financials · XBRL
- Revenue
- $56M
- +99.0% YoY
- Net income
- $4M
- +132.5% YoY
- Operating margin
- -6.5%
- EPS (diluted)
- $0.05
- +126.3% YoY
Source: XBRL data from the Protagonist Therapeutics, Inc (PTGX) Q1 2026 10-Q on SEC EDGAR. USD.
Protagonist Therapeutics, Inc Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material risk-factor changes from the December 31, 2025 Form 10-K
- Carried-forward business, operational, and financial-condition risks remain applicable
- No newly triggered regulatory, legal, compliance, liquidity, debt, currency, or concentration risks identified
- CEO trading plan covering up to 300,000 shares through October 9, 2026
- Director trading plan covering up to 27,000 shares through May 31, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Protagonist Therapeutics, Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.